drugset / Trial / NCT01350960
Multiple Ascending Dose Study of SPC5001 in Treatment of Healthy Subjects and Subjects With FH
RandomizedParallel-groupTriple-blindTreatment
Summary
The purpose is to study Safety and Tolerability.
Timeline
- Start
- 2011-05
- Primary completion
- 2011-10
- Completion
- 2011-11
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | SPC5001 | Antisense oligonucleotide | 0.5 mg/kg | Subcutaneous |
| Subject | SPC5001 | Antisense oligonucleotide | 1.5 mg/kg | Subcutaneous |
| Subject | SPC5001 | Antisense oligonucleotide | 5 mg/kg | Subcutaneous |
| Subject | SPC5001 | Antisense oligonucleotide | 10 mg/kg | Subcutaneous |